Aviceda is the world leader in glyco-immune checkpoint therapeutics. We are developing novel, immune-mediated therapies to improve the lives of patients, leading with treatment for Macular Degeneration.
Location: United States, Massachusetts, Cambridge
Total raised: $207.5M
Investors 4
| Date | Name | Website |
| 27.03.2025 | Jeito Capi... | jeito.life |
| 01.07.2025 | Omega Fund... | omegafunds... |
| 10.07.2026 | Longitude ... | longitudec... |
| 25.12.2024 | Catalio Ca... | cataliocap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.01.2025 | Series C | $207.5M | - |
Mentions in press and media 6
| Date | Title | Description |
| 10.01.2025 | Aviceda Therapeutics Secures $207.5 Million to Revolutionize Eye Care | Aviceda Therapeutics is on the rise. The Cambridge, MA-based biotech company has successfully raised $207.5 million in Series C financing. This significant funding round was led by Omega Funds and TCGX, with participation from a host of oth... |
| 08.01.2025 | Aviceda Therapeutics: $207.5 Million (Series C) Raised To Develop Next-Generation Immunomodulators | Aviceda Therapeutics, a private, clinical-stage biotech company focused on developing next-generation immunomodulators with a proprietary High Affinity Ligands of Siglecs (HALOS) nanotechnology platform to alleviate chronic, non-resolving i... |
| 08.01.2025 | Aviceda Therapeutics Raises Upsized $207.5M in Series C Financing | Aviceda Therapeutics, a Cambridge, MA-based private, clinical-stage biotech company focused on developing new immunomodulators, raised $207.5M in Series C financing. The round was led by Omega Funds and TCGX, with participation from Enavate... |
| 07.01.2025 | Aviceda raises $207M series C to take geographic atrophy drug through phase 3 | Aviceda Therapeutics has secured $207.5 million in series C funds as the immunomodulator-focused biotech awaits a phase 3 readout this year for its lead eye disease drug. The round was co-led by the healthcare funds Omega Funds and TCGX, wi... |
| 06.01.2025 | DR. KINKINI ROY SELECTED AS TOP ASSOCIATE DIRECTOR OF THE YEAR IN FORMULATION DEVELOPMENT BY IAOTP | Dr. Kinkini Roy honored member of the International Association of Top Professionals (IAOTP) will be honored at their annual awards gala in Las Vegas NEW YORK, NY, UNITED STATES, January 6, 2025 /EINPresswire.com/ -- Dr. Kinkini Roy was rec... |
| - | Aviceda Therapeutics | “Developing Next Generation Immuno-Modulators That Harness the Power of Glyco-immunology” |